Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?

Data from 1661 consecutive subjects with chronic-phase chronic myeloid leukemia (CML) receiving initial imatinib (n = 1379) or a 2(nd)-generation tyrosine-kinase inhibitor (2G-TKI; n = 282) were interrogated to determine whether the Sokal or European Treatment and Outcome Study for CML (EUTOS) long-...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiao-Shuai, Gale, Robert Peter, Huang, Xiao-Jun, Jiang, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807391/
https://www.ncbi.nlm.nih.gov/pubmed/34413457
http://dx.doi.org/10.1038/s41375-021-01387-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807391/
https://www.ncbi.nlm.nih.gov/pubmed/34413457
http://dx.doi.org/10.1038/s41375-021-01387-y

Ejemplares similares